Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market

Relentless Pursuit of Blockbuster Cardiovascular Therapeutics

Regular Price: USD 3,950

Special Price USD 3,555

10% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 3,555

PAY BY INVOICE

Be the first to review this product

Dyslipidemia exists in many forms and is prevalent in developed regions. Although many patients with moderately elevated lipids are well served by available therapies, there is a significant patient population for whom these therapies are inappropriate or inadequate, thereby prompting development of innovative therapies to fill the gaps. This research service includes comprehensive information on the market background, analyses of drug development, detailed product and pipeline analyses, detailed product profiles for key marketed/late-stage products, and a global overview. The research service also provides time-sensitive details such as new product launch timelines, PCSK9 Phase 3 programs, and patent expirations.

Table of Contents

Executive SummaryExecutive SummaryExecutive Summary (continued) Recent Market DevelopmentsDefining Healthcare Trends in the FutureCompanies to WatchMethodology and ScopeMethodology and ScopeIntroductionIntroductionMarket BackgroundLipid and Lipoprotein BasicsPrevalence of Elevated Cholesterol in Major MarketsPrevalence of Elevated Cholesterol in Major Markets (continued)Prevalence and Management of Elevated LDL-C in the United StatesClassification of Lipoprotein LevelsClassification of Familial DyslipidemiasACC/AHA Practice GuidelinesACC/AHA Practice Guidelines (continued)ACC/AHA Practice Guidelines (continued)European Practice GuidelinesMarket SegmentationMarket Segmentation (continued)Market Segmentation (continued)Competitive LandscapeCompetitive Landscape—Number of Marketed and Pipeline ProductsCompetitive Landscape—Marketed and Pipeline ProductsMarketed Product AnalysisMarketed Product Analysis (continued)Marketed Product Analysis (continued)Marketed Product Analysis (continued)Marketed Product Analysis (continued)Marketed Product Analysis (continued)Marketed Product Analysis (continued)Pipeline AnalysisPipeline Analysis—Products in Clinical Development (continued)Pipeline Analysis—Products in Clinical Development (continued)Pipeline Analysis—Products in Clinical Development (continued)Pipeline Analysis—Products in Clinical Development (continued)Pipeline Analysis—Products in Clinical Development (continued)Pipeline Analysis—Products in Clinical Development (continued)Product Launch TimelinePatent Expiration TimelinePhase 3 Clinical Program—Evolocumab (Amgen)Phase 3 Data Readouts—Evolocumab (Amgen)Phase 3 Clinical Program—Alirocumab (Sanofi/Regeneron)Phase 3 Clinical Program—Bococizumab (Pfizer)Comparative Efficacy AnalysisComparative Efficacy Analysis DiscussionProfiles of Recently Launched and Late-stage Investigational ProductsProduct Dashboard—Kynamro (mipomersen sodium)Product Dashboard—Juxtapid/Lojuxta (lomitapide)Product Dashboard—Vascepa (icosapent ethyl)Product Dashboard—Evolocumab (AMG145)Product Dashboard—Alirocumab (REGN727)Product Dashboard—Bococizumab (RN316)Conclusions and RecommendationsConclusions and RecommendationsLegal DisclaimerThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue PropositionGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 20-Nov-17

Region : North America

Release Date : 20-Nov-17

Region : North America

Release Date : 17-Nov-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.